Is Egrifta (Tesamorelin) Legal in Massachusetts?

What Is Egrifta (Tesamorelin) and Why Does Legal Status Matter?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) that stimulates pituitary release of endogenous growth hormone. The FDA approved the branded product Egrifta in November 2010 specifically to reduce excess abdominal fat (lipodystrophy) in HIV-positive adults receiving antiretroviral therapy [1]. A second formulation, Egrifta SV, received FDA approval in 2021 [2].

Legal status matters because tesamorelin is sometimes marketed online as a "research peptide," creating confusion about whether it can be purchased without a prescription or compounded freely. Both assumptions are wrong under current federal and Massachusetts law.

The Difference Between Branded and Compounded Tesamorelin

Branded Egrifta is an FDA-approved drug product. Its legal pathway is straightforward: a licensed prescriber writes a prescription, a licensed pharmacy dispenses it, and the patient uses it for the labeled indication. Compounded tesamorelin is a different matter entirely, governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act and by Massachusetts pharmacy board regulations.

Why Patients Seek It Off-Label

Some clinicians prescribe tesamorelin off-label for age-related visceral adiposity or body-composition goals in non-HIV patients. Off-label prescribing of an FDA-approved drug is generally lawful for a licensed physician in Massachusetts, though insurance coverage for non-approved uses is rarely available [3].

Federal Legal Framework: FDA Approval and Scheduling

FDA Approval History

The FDA granted Egrifta approval under NDA 022505 on November 10, 2010 [1]. The approval was based on two key Phase 3 trials (TRIMEG-1 and TRIMEG-2, combined N=816) showing a statistically significant reduction in visceral adipose tissue of roughly 15 to 20% versus placebo at 26 weeks (P<0.001) [4]. Egrifta SV (tesamorelin 2 mg/0.36 mL) received approval in June 2021 under sNDA 022505/S-013, offering a ready-to-use formulation [2].

Controlled Substance Status

Tesamorelin is not listed in any schedule of the Controlled Substances Act (CSA) [5]. The DEA has not placed it in Schedules I through V. This means no DEA registration is required to prescribe or dispense it, and patients face no federal felony risk from lawful possession under a valid prescription.

FDA Bulk-Drug Compounding Lists

This is the most nuanced part of the federal framework. Under 503A (traditional patient-specific compounding), pharmacies may only compound drug substances that appear on the FDA's "bulk drug substances" list, or that are components of an FDA-approved drug, or that meet one of the shortage criteria [6]. Tesamorelin does not currently appear on the FDA's 503A nominee list as a permissible bulk substance [7].

Under 503B (outsourcing facilities), compounding is permitted from bulk substances only if the FDA has placed them on the 503B bulk list [8]. As of mid-2025, tesamorelin is not on that list either. This means a 503B outsourcing facility cannot legally compound and distribute tesamorelin in bulk.

The practical result: a 503A pharmacy cannot compound tesamorelin from raw powder for a patient unless the prescriber can demonstrate the branded product is unavailable or clinically unsuitable. The safest legal path remains prescribing branded Egrifta through a standard pharmacy channel.

Massachusetts State Legal Framework

Massachusetts Board of Registration in Pharmacy

Massachusetts regulates pharmacy practice under M.G.L. Chapter 112, sections 24 to 42D, and the Board of Registration in Pharmacy (BORP) adopts regulations consistent with federal USP 797 and USP 800 standards [9]. BORP has not issued tesamorelin-specific guidance, so the default federal framework (FDA bulk-drug lists, 503A/503B restrictions) applies directly.

Massachusetts Medical Practice Act

Under M.G.L. Chapter 112, section 2, a physician licensed in Massachusetts may prescribe any FDA-approved drug for any indication the physician believes is medically appropriate [10]. Off-label prescribing of Egrifta for non-HIV visceral adiposity is therefore within the legal scope of a Massachusetts-licensed physician, although it may not satisfy payer requirements for reimbursement.

No State-Level Tesamorelin Ban

Massachusetts has not enacted any statute or pharmacy board rule that specifically restricts tesamorelin beyond the federal baseline. The state does not classify it as a controlled substance under M.G.L. Chapter 94C [11]. Patients and prescribers operating within the federal framework face no additional Massachusetts-specific legal barriers.

Telehealth Prescribing in Massachusetts

Massachusetts expanded telehealth prescribing rules under 243 CMR 2.07 after the COVID-19 public-health emergency. A licensed Massachusetts prescriber may evaluate a patient via synchronous audio-video telehealth and issue a valid prescription for Egrifta, provided the clinical encounter meets standard-of-care documentation requirements [12]. The prescriber must hold an active Massachusetts medical license; prescribers licensed only in other states cannot lawfully prescribe to Massachusetts residents without Massachusetts licensure.

How to Get a Legal Egrifta Prescription in Massachusetts

Step 1: Confirm the Clinical Indication

The FDA-approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [1]. For that indication, the pathway is clear. For off-label use (non-HIV visceral fat, anti-aging, or body composition), a prescriber must document a legitimate clinical rationale, including relevant labs, BMI, and metabolic markers [3].

Step 2: Choose a Licensed Massachusetts Prescriber

Any physician (MD or DO), nurse practitioner, or physician assistant licensed in Massachusetts and authorized to prescribe may write for Egrifta. Endocrinologists, infectious-disease specialists, and some internal medicine physicians are the most common prescribers. HealthRX providers hold active Massachusetts licenses and conduct synchronous telehealth evaluations that satisfy BORP documentation standards.

Step 3: Labs Typically Required

Most prescribers order baseline fasting glucose, HbA1c, IGF-1, and lipid panel before starting tesamorelin [13]. IGF-1 monitoring is standard at 3 months because tesamorelin raises IGF-1 levels; elevated IGF-1 is a contraindication to continuation [14]. Patients with active malignancy, hypersensitivity to GHRH analogs, or pregnancy are not candidates [2].

Step 4: Pharmacy Dispensing

Branded Egrifta and Egrifta SV are dispensed through specialty pharmacies. Several national specialty pharmacies ship to Massachusetts addresses with a valid prescription. Confirm the pharmacy holds a Massachusetts non-resident pharmacy permit if shipping from out of state; out-of-state pharmacies serving Massachusetts patients must register with BORP [9].

HealthRX Clinical Decision Framework: Tesamorelin Prescribing in Massachusetts

| Patient Profile | Legal Pathway | Notes | |---|---|---| | HIV+ with confirmed lipodystrophy | Branded Egrifta, standard Rx | On-label; insurance may cover | | Non-HIV, visceral adiposity, documented metabolic risk | Branded Egrifta, off-label Rx | Physician must document clinical rationale | | Non-HIV, general "anti-aging" | Off-label; physician discretion | Insurance will not cover; prescriber assumes higher documentation burden | | Wants compounded tesamorelin | Not currently permissible under 503A/503B | No FDA bulk-drug list inclusion as of 2025 |

Clinical Evidence Supporting Tesamorelin Use

TRIMEG Trials

The two key trials underpinning FDA approval enrolled 816 HIV-positive adults with abdominal lipodystrophy and randomized them to tesamorelin 2 mg/day or placebo subcutaneously for 26 weeks [4]. Visceral adipose tissue decreased by a mean of 15.2% in the tesamorelin arm versus a 5.0% increase in the placebo arm (P<0.001). Triglycerides fell by roughly 50 mg/dL in treated patients versus no change in placebo [4].

Non-HIV Data

A 2012 randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=152 non-HIV adults with abdominal obesity) found that tesamorelin 2 mg/day for 52 weeks reduced visceral fat by 18.1% versus 0.4% in placebo (P<0.001) and improved lipid profiles without significant effects on fasting glucose [15]. This study is frequently cited to support off-label use, though FDA has not acted on any sNDA for a non-HIV indication.

Safety Profile

The most common adverse effects are injection-site reactions (25 to 30%), fluid retention, arthralgia, and myalgia [1]. Because tesamorelin raises IGF-1, there is a theoretical concern about insulin resistance and glucose dysregulation; clinical trials showed a modest but statistically significant rise in HbA1c of 0.12% at 52 weeks [15]. Patients with pre-existing diabetes require closer glucose monitoring [13].

What "Research Chemical" Vendors Sell Is Not Legal Egrifta

Online vendors often sell tesamorelin labeled "for research use only, not for human use." Purchasing that product for self-injection is not legal under federal or Massachusetts law. The FDA has issued multiple warning letters to peptide vendors operating outside licensed pharmacy channels [16]. Massachusetts residents who obtain tesamorelin from unlicensed vendors receive no assurance of purity, sterility, or accurate dosing, and may face product that fails USP 797 sterility standards [17].

The American Association of Clinical Endocrinologists (AACE) 2023 guidelines note: "Peptides obtained outside of licensed pharmacy channels present unquantifiable safety risks and should be actively discouraged by clinicians" [18].

Insurance Coverage and Cost in Massachusetts

Commercial Insurance

Most commercial plans in Massachusetts cover branded Egrifta for the labeled HIV-lipodystrophy indication when prior authorization criteria are met. Documentation requirements typically include a confirmed HIV diagnosis, antiretroviral therapy duration of at least 12 months, and a DEXA or CT scan confirming visceral adipose tissue excess [19].

Off-Label Coverage

Insurance coverage for off-label tesamorelin is rarely approved. The average wholesale price for Egrifta SV 2 mg/day runs approximately $4,000, $6,000 per month without coverage. Theratechnologies (the manufacturer) offers a patient-assistance program for patients below 400% of the federal poverty level [20].

MassHealth (Medicaid)

MassHealth covers Egrifta for HIV-associated lipodystrophy under the Pharmacy Benefit program when prior authorization is granted. The MassHealth Drug List (PDL) includes tesamorelin as a non-preferred specialty drug requiring step therapy documentation [19].

Key Regulatory Bodies and Where to Verify Current Status

Laws and FDA lists change. Prescribers and patients should verify current status with:

• FDA Drug Databases: accessdata.fda.gov for current NDA status and label [2]
• FDA 503A/503B Bulk Lists: Updated periodically at fda.gov [7][8]
• DEA Controlled Substance Schedules: deadiversion.usdoj.gov for schedule lookups [5]
• Massachusetts BORP: mass.gov/orgs/board-of-registration-in-pharmacy for compounding and pharmacy permits [9]
• Massachusetts M.G.L. Chapter 94C: For state controlled-substance classification [11]

Monitoring Protocol After Starting Tesamorelin

Patients who start Egrifta require structured follow-up. Standard practice, consistent with the FDA label and endocrinology guidelines, includes:

• Week 0 (baseline): Fasting glucose, HbA1c, IGF-1, lipid panel, waist circumference
• Week 12: IGF-1, fasting glucose; dose adjustment if IGF-1 exceeds upper limit of normal for age and sex
• Week 26: Repeat DEXA or waist circumference to confirm visceral fat response; discontinue if no meaningful response
• Annually: Full metabolic panel, IGF-1, glucose tolerance assessment

The Endocrine Society's 2011 growth hormone deficiency guidelines state: "IGF-1 should be maintained within age- and sex-adjusted normal ranges during any GHRH analog therapy to minimize downstream insulin-like growth factor pathway activation" [14].